Furthermore, MC4R-agonism enhances peripheral insulin sensitivity and improves glucose tolerance in rodents and non-human primates (Obici et al, 2001; Kievit et al, 2013), implying that MC4R-based drug therapies hold promise for treatment of type 2 diabetes and obesity. The gene discussed is MC4R; the disease is obesity due to melanocortin 4 receptor deficiency.